

Freedom of Information Request

Ref: 24-517

1 July 2024

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of Jan 2024 to the end of Mar 2024 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

If data is unavailable for question 1 it would be helpful if you can provide the information at a department level (question 2).

Appendix A

Q1 – How many patients were treated with the following drugs for the following diseases from the start of Jan 2024 to the end of Mar 2024?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)						
Adalimumab (Biosimilars)						

Apremilast						
Bimekizumab						
Brodalumab						
Certolizumab Pegol						
Deucravacitinib						
Etanercept (Enbrel)						
Etanercept (Biosimilars)						
Guselkumab						
Infliximab (Remicade)						
Infliximab (Biosimilars)						
Ixekizumab						
Risankizumab						
Secukinumab						
Tildrakizumab						
Ustekinumab						
Upadacitinib						
Vedolizumab						
Filgotinib						
Golimumab						
Mirikizumab						
Ozanimod						
Tofacitinib						
Baricitinib						
Rituximab						
Sarilumab						
Tocilizumab						

Please note that we cannot provide this information by the specific disease - our system does not capture the information in this way.

Q2 – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2024 to the end of Mar 2024?
Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Please see the table below.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	*	6	32
Adalimumab (Biosimilars)	362	470	611
Apremilast	14	0	*
Bimekizumab	6	0	0
Brodalumab	21	0	0
Certolizumab Pegol	13	*	77
Deucravacitinib	*	0	0
Etanercept (Enbrel)	*	0	22
Etanercept (Biosimilars)	11	*	276
Guselkumab	17	0	9
Infliximab (Remicade)	0	0	8
Infliximab (Biosimilars)	7	266	163
Ixekizumab	27	0	26
Risankizumab	57	10	*
Secukinumab	49	0	83
Tildrakizumab	0	0	0
Ustekinumab	60	156	12
Upadacitinib	61	54	6
Vedolizumab	0	117	50
Filgotinib	0	11	13
Golimumab	0	10	31

Mirikizumab	0	0	0
Ozanimod	0	0	0
Tofacitinib	0	35	15
Baricitinib	*	0	22
Rituximab	0	0	81
Sarilumab	0	0	28
Tocilizumab	0	0	73

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust